165 lines
47 KiB
Text
165 lines
47 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK23033">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK23033/?report=reader">
|
|
<meta name="ncbi_pagename" content="4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/TrastFab111In/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/mIgGtat111In/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2007/12/18">
|
|
<meta name="citation_author" content="Kenneth T. Cheng">
|
|
<meta name="citation_author" content="Chang H. Paik">
|
|
<meta name="citation_author" content="Narasimhan Danthi">
|
|
<meta name="citation_pmid" content="20641240">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK23033/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Kenneth T. Cheng">
|
|
<meta name="DC.Contributor" content="Chang H. Paik">
|
|
<meta name="DC.Contributor" content="Narasimhan Danthi">
|
|
<meta name="DC.Date" content="2007/12/18">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK23033/">
|
|
<meta name="description" content="4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine (IAC-SCN-Bz-DOTA-111In) is an integrin-targeted molecular imaging agent conjugated with 111In that was developed for single-photon emission computed tomography (SPECT) or planar gamma imaging of tumor vasculature and tumor angiogenesis (1). 111In is a gamma emitter with a physical half-life (t½) of 2.8 days.">
|
|
<meta name="og:title" content="4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine (IAC-SCN-Bz-DOTA-111In) is an integrin-targeted molecular imaging agent conjugated with 111In that was developed for single-photon emission computed tomography (SPECT) or planar gamma imaging of tumor vasculature and tumor angiogenesis (1). 111In is a gamma emitter with a physical half-life (t½) of 2.8 days.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK23033/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/IAC111In/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK23033/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8B21B77D64E0810000000000030003.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK23033/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/TrastFab111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/mIgGtat111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK23033/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK23033/&text=4-%5B2-(3%2C4%2C5%2C6-Tetrahydropyrimidin-2-ylamino)ethyloxy%5Dbenzoyl-2-(S)-%5BN-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-c..."><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK23033/?report=classic">Switch to classic view</a><a href="/books/NBK23033/pdf/Bookshelf_NBK23033.pdf">PDF (391K)</a><a href="/books/NBK23033/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK23033%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8B21B77D64E0810000000000030003.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK23033_"><span class="title" itemprop="name">4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(<i>S</i>)-[<i>N</i>-3-amino-(SCN-Bz-DOTA-<sup>111</sup>In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">IAC-SCN-Bz-DOTA-<sup>111</sup>In</div><p class="contribs">Cheng KT, Paik CH, Danthi N.</p><p class="fm-aai"><a href="#_NBK23033_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figIAC111InT1"><a href="/books/NBK23033/table/IAC111In.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figIAC111InT1" rid-ob="figobIAC111InT1"><img class="small-thumb" src="/books/NBK23033/table/IAC111In.T1/?report=thumb" src-large="/books/NBK23033/table/IAC111In.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="IAC111In.T1"><a href="/books/NBK23033/table/IAC111In.T1/?report=objectonly" target="object" rid-ob="figobIAC111InT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="IAC111In.Background"><h2 id="_IAC111In_Background_">Background</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD)" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(<i>S</i>)-[<i>N</i>-3-amino-(SCN-Bz-DOTA-<sup>111</sup>In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine (IAC-SCN-Bz-DOTA-<sup>111</sup>In) is an integrin-targeted molecular imaging agent conjugated with <sup>111</sup>In that was developed for single-photon emission computed tomography (SPECT) or planar gamma imaging of tumor vasculature and tumor angiogenesis (<a class="bibr" href="#IAC111In.EXTYLES.1" rid="IAC111In.EXTYLES.1">1</a>). <sup>111</sup>In is a gamma emitter with a physical half-life (<i>t</i><sub>½</sub>) of 2.8 days.</p><p>Cellular survival, invasion, and migration control embryonic development, angiogenesis, tumor metastasis, and other physiological processes (<a class="bibr" href="#IAC111In.EXTYLES.2" rid="IAC111In.EXTYLES.2">2</a>, <a class="bibr" href="#IAC111In.EXTYLES.3" rid="IAC111In.EXTYLES.3">3</a>). Among the molecules that regulate angiogenesis are integrins, which comprise a superfamily of cell adhesion proteins that form heterodimeric receptors for extracellular matrix (ECM) molecules (<a class="bibr" href="#IAC111In.EXTYLES.4" rid="IAC111In.EXTYLES.4">4</a>, <a class="bibr" href="#IAC111In.EXTYLES.5" rid="IAC111In.EXTYLES.5">5</a>). These transmembrane glycoproteins consist of two noncovalently associated subunits, α and β (18 α- and 8 β-subunits in mammals), which are assembled into at least 24 α/β pairs. Several integrins, such as integrin α<sub>v</sub>β<sub>3</sub>, have affinity for the arginine-glycine-aspartic acid (RGD) tripeptide motif, which is found in many ECM proteins. Expression of integrin α<sub>v</sub>β<sub>3</sub> receptors on endothelial cells is stimulated by angiogenic factors and environments. The integrin α<sub>v</sub>β<sub>3</sub> receptor is generally not found in normal tissue, but it is strongly expressed in vessels with increased angiogenesis, such as tumor vasculature. It is significantly upregulated in certain types of tumor cells and in almost all tumor vasculature. Molecular imaging probes carrying the RGD motif that binds to the integrin α<sub>v</sub>β<sub>3</sub> can be used to image tumor vasculature and evaluate angiogenic response to tumor therapy (<a class="bibr" href="#IAC111In.EXTYLES.6" rid="IAC111In.EXTYLES.6">6</a>, <a class="bibr" href="#IAC111In.EXTYLES.7" rid="IAC111In.EXTYLES.7">7</a>).</p><p>Various RGD peptides in both linear and cyclic forms have been developed for <i>in vivo</i> binding to integrin α<sub>v</sub>β<sub>3</sub> (<a class="bibr" href="#IAC111In.EXTYLES.8" rid="IAC111In.EXTYLES.8">8</a>). Non-peptide integrin α<sub>v</sub>β<sub>3</sub>–targeted molecular probes have also been investigated (<a href="#IAC111In.EXTYLES.9">9-11</a>). Duggan et al. (<a class="bibr" href="#IAC111In.EXTYLES.10" rid="IAC111In.EXTYLES.10">10</a>) modified a potent fibrinogen receptor antagonist from the sulfonamide exo-site class to generate non-peptide compounds with high affinity for the integrin α<sub>v</sub>β<sub>3</sub> receptor. The centrally -constrained benzoylamino-3-propionic acid scaffold appeared to provide optimum spacing between the acidic and basic portions of these ligands for binding. Based on the potent α<sub>v</sub>β<sub>3</sub> inhibitor 4-[2-(3,4,5,6-tetrahydropyrimidine-2-ylamino)ethyloxy]benzoyl-2-(<i>S</i>)-aminoethylsulfonyl-amino-β-alanine (IA) which has a 50% inhibitory concentration (IC<sub>50</sub>) of 0.04 μM and was used by Hood et al. (<a class="bibr" href="#IAC111In.EXTYLES.11" rid="IAC111In.EXTYLES.11">11</a>) to covalently couple to a cationic nanoparticle for targeted gene therapy, Burnett et al. (<a class="bibr" href="#IAC111In.EXTYLES.9" rid="IAC111In.EXTYLES.9">9</a>) designed and synthesized a series of aliphatic carbamate derivatives with enhanced binding affinity. The peptidomimetic 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(<i>S</i>)-[<i>N</i>-(3-amino-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine hydrochloride (IAC) ligand was conjugated to a fluorescence label (FITC-IAC) as an integrin α<sub>v</sub>β<sub>3</sub> molecular probe for optical imaging of α<sub>v</sub>β<sub>3</sub>-expressing tumors. To develop a radioligand for SPECT imaging, Jang et al. (<a class="bibr" href="#IAC111In.EXTYLES.1" rid="IAC111In.EXTYLES.1">1</a>) successfully prepared IAC-SCN-Bz-DOTA-<sup>111</sup>In for studies in nude mice bearing the human M21 melanoma tumor.</p></div><div id="IAC111In.Synthesis"><h2 id="_IAC111In_Synthesis_">Synthesis</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD)" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Burnett et al. (<a class="bibr" href="#IAC111In.EXTYLES.9" rid="IAC111In.EXTYLES.9">9</a>) reported the synthesis of IAC from commercially available amino alcohol. The amine was first protected as the <i>t</i>-butoxycarbonyl (<i>t</i>-Boc) derivative and then activated as 3-(Boc-amino)neopentyl-1-<i>O</i>-carbonylimidazole. The activated alcohol was then coupled to the free amine of IA to provide the Boc carbamate. The Boc carbamate was deprotected with anhydrous hydrochloric acid in dioxane to yield IAC. For radiolabeling, a bifunctional chelate was first conjugated to the amino terminus of IAC. Commercially obtained 2-(<i>p</i>-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-<i>N</i>,<i>N'</i>,<i>N''</i>,<i>N'''</i>-tetraacetic acid (SCN-Bz-DOTA) was reacted with IAC in 0.1 M sodium bicarbonate (pH 8.4) for 2 days at room temperature (<a class="bibr" href="#IAC111In.EXTYLES.1" rid="IAC111In.EXTYLES.1">1</a>). A 10:1 molar ratio of IAC to SCN-Bz-DOTA appeared to give a quantitative yield of the IAC-SCN-Bz-DOTA conjugate. The authors suggested that the product formed was a 1:1 conjugate because the primary amine was the only reactive functional group at pH 8.4. This conjugate was purified with a Sep-Pak C-18 cartridge and then incubated with <sup>111</sup>In-chloride in an aqueous solution (pH 5) of 0.23 M sodium acetate and 0.015 M sodium ascorbate at 75ºC for 1 h. The final radioligand was purified with a Sep-Pak C-18 cartridge. The labeling yield was >80%. The specific activity was calculated to be >7.5 kBq/pmol (202.7 Ci/mmol). Preparations with >95% radiochemical purity were used for <i>in vitro</i> and <i>in vivo</i> studies.</p></div><div id="IAC111In.In_Vitro_Studies_Tes"><h2 id="_IAC111In_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=((radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD))+AND+in+vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Burnett et al. (<a class="bibr" href="#IAC111In.EXTYLES.9" rid="IAC111In.EXTYLES.9">9</a>) used the enzyme-linked immunosorbent assay to determine the IC<sub>50</sub> of unlabeled IAC to be 2.94 nM. <i>In vitro</i> binding assays of IAC-SCN-Bz-DOTA-<sup>111</sup>In were performed with purified human α<sub>v</sub>β<sub>3</sub> protein (molecular weight = 237,000) (<a class="bibr" href="#IAC111In.EXTYLES.1" rid="IAC111In.EXTYLES.1">1</a>). The binding was assessed by size-exclusion high-performance liquid chromatography to detect the shift to a higher molecular weight peak that was identical to the integrin α<sub>v</sub>β<sub>3</sub> protein. The percent bound of IAC-SCN-Bz-DOTA-<sup>111</sup>In was 6%, 40%, and 72% when incubated with 0.08 μM, 0.4 μM, and 0.8 μM integrin α<sub>v</sub>β<sub>3</sub>, respectively. This binding was completely blocked by a 25-fold molar excess of unlabeled IA. The authors reported that IAC-SCN-Bz-DOTA-<sup>111</sup>In was stable in serum for 18 h at 37ºC.</p></div><div id="IAC111In.Animal_Studies"><h2 id="_IAC111In_Animal_Studies_">Animal Studies</h2><div id="IAC111In.Rodents"><h3>Rodents</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD)" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The <i>in vivo</i> tumor accumulation, distribution, and gamma imaging of IAC-SCN-Bz-DOTA-<sup>111</sup>In were studied in nude mice bearing s.c. human M21 melanomas (~0.5 cm<sup>3</sup>) in the right flanks (<a class="bibr" href="#IAC111In.EXTYLES.1" rid="IAC111In.EXTYLES.1">1</a>). Unlabeled IAC was added to the radioligand to achieve the specific activity of 85 kBq/<160 pmol (2.30 μCi/<160 pmol) so that each mouse received 160 pmol of total IAC. The radioligand was rapidly cleared from the circulation <i>via</i> the renal system. The tumor radioactivity levels (<i>n</i> = 4–5) were 5.58 ± 1.43% injected dose per gram (ID/g) (20 min), 5.34 ± 0.60% ID/g (60 min), and 4.47 ± 0.66% ID/g (120 min). In most major organs (except the lung and kidney), the tumor/organ ratios at 20 min were all >1. The tumor/blood ratios were 2.36 ± 0.64 (20 min), 4.69 ± 1.30 (60 min), and 9.74 ± 1.00 (120 min). The tumor/muscle ratios were 4.99 ± 1.46 (20 min), 7.07 ± 1.48 (60 min), and 9.87 ± 1.22 (120 min). The tumor/kidney ratios were 0.19 ± 0.07 (20 min), 0.37 ± 0.07 (60 min), and 0.78 ± 0.12 (120 min). The tumor/liver ratios were 1.58 ± 0.60 (20 min), 1.79 ± 0.31 (60 min), and 2.26 ± 0.35 (120 min). The tumor/intestine ratios were 1.01 ± 0.38 (20 min), 1.00 ± 0.15 (60 min), and 0.92 ± 0.13 (120 min). In a blocking study, 200 μg of unlabeled IA was co-injected with <sup>111</sup>In-SCN-Bz-DOTA-IAC. At 60 min after injection, the tumor radioactivity level was decreased from 5.3 ± 0.6% ID/g to 1.4 ± 0.3% ID/g. The radioactivity levels in most other organs were also significantly decreased. Co-injection of 30 mg <span class="small-caps">l</span>-lysine did not decrease either the tumor or kidney radioactivity level. The static posterior gamma imaging of the mice at 4 h after injection clearly visualized the tumor, and this visualization remained for 72 h. The abdomen and bladder areas were visualized at 4 h but gradually cleared out. With co-injection of 200 μg unlabeled IA, the tumor was not distinguished from the surrounding background radioactivity.</p></div><div id="IAC111In.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=((radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD))+AND+(dog+OR+rabbit+OR+pig+OR+sheep)" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="IAC111In.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=((radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD))+AND+(primate+NOT+human)" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div></div><div id="IAC111In.Human_Studies"><h2 id="_IAC111In_Human_Studies_">Human Studies</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=((radiolabeled+IAC)+OR+(peptidomimetic+antagonist+for+imaging+of+RGD))+AND+human" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="IAC111In.NIH_Support"><h2 id="_IAC111In_NIH_Support_">NIH Support</h2><p>NIH Intramural Support.</p></div><div id="IAC111In.references"><h2 id="_IAC111In_references_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.1">Jang B.S. , Lim E. , Hee Park S. , Shin I.S. , Danthi S.N. , Hwang I.S. , Le N. , Yu S. , Xie J. , Li K.C. , Carrasquillo J.A. , Paik C.H. Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice. <span><span class="ref-journal">Nucl Med Biol. </span>2007;<span class="ref-vol">
|
|
<strong>34</strong>
|
|
</span>(4):363–70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17499725" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17499725</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.2">Jin H. , Varner J. Integrins: roles in cancer development and as treatment targets. <span><span class="ref-journal">Br J Cancer. </span>2004;<span class="ref-vol">
|
|
<strong>90</strong>
|
|
</span>(3):561–5.</span> [<a href="/pmc/articles/PMC2410157/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2410157</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14760364" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14760364</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.3">Paulhe F. , Manenti S. , Ysebaert L. , Betous R. , Sultan P. , Racaud-Sultan C. Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer. <span><span class="ref-journal">Curr Pharm Des. </span>2005;<span class="ref-vol">
|
|
<strong>11</strong>
|
|
</span>(16):2119–34.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15974963" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15974963</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.4">Hood J.D. , Cheresh D.A. Role of integrins in cell invasion and migration. <span><span class="ref-journal">Nat Rev Cancer. </span>2002;<span class="ref-vol">
|
|
<strong>2</strong>
|
|
</span>(2):91–100.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12635172" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12635172</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.5">Hwang R. , Varner J. The role of integrins in tumor angiogenesis. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2004;<span class="ref-vol">
|
|
<strong>18</strong>
|
|
</span>(5):991–1006.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15474331" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15474331</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.6">Cai W. , Shin D.W. , Chen K. , Gheysens O. , Cao Q. , Wang S.X. , Gambhir S.S. , Chen X. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. <span><span class="ref-journal">Nano Lett. </span>2006;<span class="ref-vol">
|
|
<strong>6</strong>
|
|
</span>(4):669–76.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16608262" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16608262</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.7">Massoud T.F. , Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. <span><span class="ref-journal">Genes Dev. </span>2003;<span class="ref-vol">
|
|
<strong>17</strong>
|
|
</span>(5):545–80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12629038" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12629038</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.8">Haubner R. , Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. <span><span class="ref-journal">Curr Pharm Des. </span>2004;<span class="ref-vol">
|
|
<strong>10</strong>
|
|
</span>(13):1439–55.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15134568" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15134568</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.9">Burnett C.A. , Xie J. , Quijano J. , Shen Z. , Hunter F. , Bur M. , Li K.C. , Danthi S.N. Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor. <span><span class="ref-journal">Bioorg Med Chem. </span>2005;<span class="ref-vol">
|
|
<strong>13</strong>
|
|
</span>(11):3763–71.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15863003" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15863003</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.10">Duggan M.E. , Duong L.T. , Fisher J.E. , Hamill T.G. , Hoffman W.F. , Huff J.R. , Ihle N.C. , Leu C.T. , Nagy R.M. , Perkins J.J. , Rodan S.B. , Wesolowski G. , Whitman D.B. , Zartman A.E. , Rodan G.A. , Hartman G.D. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. <span><span class="ref-journal">J Med Chem. </span>2000;<span class="ref-vol">
|
|
<strong>43</strong>
|
|
</span>(20):3736–45.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11020288" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11020288</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="IAC111In.EXTYLES.11">Hood J.D. , Bednarski M. , Frausto R. , Guccione S. , Reisfeld R.A. , Xiang R. , Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. <span><span class="ref-journal">Science. </span>2002;<span class="ref-vol">
|
|
<strong>296</strong>
|
|
</span>(5577):2404–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12089446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12089446</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><div>This MICAD chapter is not included in the Open Access Subset, because it was authored / co-authored by one or more investigators who was not a member of the MICAD staff.</div></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK23033_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Kenneth T. Cheng</span>, PhD<div class="affiliation small">
|
|
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a>
|
|
</div></div><div class="contrib half_rhythm"><span itemprop="author">Chang H. Paik</span>, PhD<div class="affiliation small">
|
|
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, NIH, Bethesda, MD, Corresponding Author,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@kiapc" class="oemail">vog.hin.liam@kiapc</a>
|
|
</div></div><div class="contrib half_rhythm"><span itemprop="author">Narasimhan Danthi</span>, PhD<div class="affiliation small">
|
|
Department of Radiology, Warren G. Magnuson Clinical Center, NIH, Bethesda, MD,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.cc@ihtnaDN" class="oemail">vog.hin.cc@ihtnaDN</a>
|
|
</div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">July 9, 2007</span>; Last Update: <span itemprop="dateModified">December 18, 2007</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Cheng KT, Paik CH, Danthi N. 4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine. 2007 Jul 9 [Updated 2007 Dec 18]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/TrastFab111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/mIgGtat111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobIAC111InT1"><div id="IAC111In.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK23033/table/IAC111In.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__IAC111In.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(<i>S</i>)-[<i>N</i>-3-amino-(SCN-Bz-DOTA-<sup>111</sup>In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine</td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/26657387" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=26657387" alt="image 26657387 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IAC-SCN-Bz-DOTA-<sup>111</sup>In</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In-IAC, IAC-2-(<i>p</i>-isothiocyanatobenzyl)-DOTA-<sup>111</sup>In</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compound</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Integrin α<sub>v</sub>β<sub>3</sub></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Receptor binding</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Single-photon emission computed tomography (SPECT), planar gamma imaging</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click on the above structure for additional information in <a href="http://pubchem.ncbi.nlm.nih.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubChem</a>.<br />Click on <a href="/entrez/viewer.fcgi?db=protein&val=4504763" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">protein</a>, <a href="/entrez/viewer.fcgi?db=nucleotide&val=40217844" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">nucleotide</a> (RefSeq), and <a href="/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=3685" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">gene</a> for more information about integrin α<sub>v</sub>β<sub>3</sub>.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|